Abstract:
The present invention relates to a joint distractor (1) for the spine, which joint distractor comprises a bone anchor (2) for attaching the joint distractor to a vertebrae, in particular a pedicle of the vertebrae, wherein the bone anchor comprises a forward longitudinal element (3) having a smooth outer surface (4) and comprises a passage (5) for receiving a Kirschner wire in a sliding manner. The bone anchor comprising a forward longitudinal element having a smooth outer surface and comprising a passage for receiving a Kirschner wire (22) in a sliding manner enables to push the bone anchor in the vertebrae while making use of guidance given by the Kirschner wire.
Abstract:
The invention relates to the fields of medicine and virology, more in particular to means and methods for treating a viral disease caused by flaviviruses or alphaviruses. Provided is tomatidine or an analog thereof for use in a method of treating a viral infection caused by a flavivirus or an alphavirus, such as dengue virus or Chikungunya virus. Also provided is a pharmaceutical composition comprising tomatidine or an analog thereof, and at least one further antiviral agent.
Abstract:
A system for providing multiple infusions to a patient (P), the system comprises a multiplicity of infusion devices (10) for administering a multiplicity of medical fluids through an infusion line (102) of an infusion set (103) to the patient (P), and a control device (2) for controlling the multiplicity of infusion devices (10). Herein, the control device (2) comprises a multiplex module (22) configured to multiplex the multiplicity of medical fluids for a multiplexed administration of the medical fluids through said infusion line (102) of the infusion set (103), the multiplex module (22) comprising a scheduling module (222) configured to define at least two packets, each packet comprising at least one medical fluid out of the multiplicity of medical fluids, and to arrange the at least two packets in a sequence for administration of the medical fluids of the at least two packets. In this way a system for providing multiple infusions to a patient is provided which allows for an efficient, yet reliable administration of multiple infusions while at the same time reducing the risks for errors. An advantage of multiplexing is reduction of the number of lumens with associated reduction of infection risks and discomfort.
Abstract:
The invention relates to analytical chemistry, in particular to means and methods for the quantitative determination of derivatized biogenic amines, precursors or metabolites thereof. Provided is a method for the in situ derivatization of at least one biogenic amine, precursor or metabolite thereof in an isolated aqueous sample, the derivatization comprising the steps of: (i) contacting said sample with a propionic anhydride / acetonitril solution in the presence of a phosphate buffer having a pH in the range of 7.0 to 9.0 and allowing the conversion of amine and/or hydroxyl moieties of said biogenic amine or metabolite thereof to form a propionyl derivative of said biogenic amine; followed by (ii) adding to the reaction mixture obtained in step (i) a carbodiimide compound and an electrophilic amine-containing compound, and allowing the carbodiimide-mediated derivatization of carboxylic acid moieties of a biogenic amine, precursor or metabolite thereof.
Abstract:
The invention relates to the field of tissue engineering and cell-based therapy. More in particular, it relates to an oxygen-releasing biomaterial that can enhance and support cell survival in vivo. Provided is an oxygen-delivering microsphere based on a biocompatible polymer, the microsphere comprising an agent capable of generating oxygen in situ encapsulated in a polymer matrix comprising poly (1,3-trimethylene carbonate) (PTMC). Also provided is an implantable device, like a scaffold for tissue engineering, comprising a plurality of oxygen-delivering microparticles according to the invention.
Abstract:
The invention relates to the fields of microbiology, dentistry and the manufacture of antibacterial products, more in particular to printable polymerizable composite resins that have antimicrobial properties. Provided is a photocurable antibacterial resin composition, comprising (i) a polymer matrix comprising at least one biocompatible polymerizable acrylic compound; (ii) a photoinitiator system; and (iii) a methacrylate-modified positively charged compound (PCC) having antibacterial properties, wherein the PCC is present in the composition as polymeric PCC (p PCC) obtained by polymerization of methacrylate-modified PCC monomers.
Abstract:
The invention relates to a method of connecting a lead to cardiac tissue in a patient's body, comprising the steps of: a) providing an elongated hollow delivery tool having a proximal end and a distal end, b) inserting the distal end of the tool into the patient's body, c) navigating the delivery tool until its distal end contacts the cardiac tissue at a contact location, d) determining if the contact location is suitable for connection of the lead, e) if the contact location is deemed suitable, fixedly connecting an electrode of the lead to the cardiac tissue at that location, and f) if the contact location is not deemed suitable, moving the distal end of the delivery tool away from the cardiac tissue and navigating the delivery tool until its distal end contacts the cardiac tissue at an alternative contact location that is spaced apart from the previous contact location, and repeating step d). The invention further relates to a system for connecting a lead to cardiac tissue in a patient's body, comprising: an elongated hollow delivery tool having a proximal end and a distal end, the distal end being arranged for insertion into the patient's body, a navigating device for navigating the distal end of the delivery tool to a contact location on the cardiac tissue, a determinator for determining the suitability of the contact location, and a connecting device for fixedly connecting an electrode of the lead to the cardiac tissue at a selected contact location.
Abstract:
The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.
Abstract:
The invention relates to the field of immunology and vaccine development. In particular, it relates to antibodies and fragments thereof against Staphylococcus aureus and to therapeutic and diagnostic uses thereof. Provided is an isolated antibody or a functional fragment thereof, which binds to an epitope of the Immunodominant Staphylococcal antigen A (IsaA), wherein said antibody comprises at least four Isa A epitope-binding CDR sequences selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6, and functional equivalents thereof having an amino acid sequence that is at least 85% identical to an amino acid sequence of SEQ ID NO: 1-6.
Abstract translation:本发明涉及免疫学和疫苗开发领域。 特别地,其涉及抗金黄色葡萄球菌的抗体及其片段及其治疗和诊断用途。 提供了与免疫显性葡萄球菌抗原A(IsaA)的表位结合的分离抗体或其功能片段,其中所述抗体包含至少四种IsaA表位结合CDR序列,其选自SEQ ID NO: 1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6及其功能等同物,其具有与SEQ ID NO:1-6的氨基酸序列至少85%相同的氨基酸序列。
Abstract:
Biomarkers useful for prognosis, selection and monitoring of kidney disease or risk thereof are provided. In particular, proteins whose expression patterns are strongly predictive of the risk of developing or presence of kidney disease are identified. A method for identifying a subject who is at risk for or suffering from kidney disease and optionally managing the subject's treatment accordingly using the biomarkers is also provided.